NZ793855A - Methods of treating pulmonary fibrosis - Google Patents

Methods of treating pulmonary fibrosis

Info

Publication number
NZ793855A
NZ793855A NZ793855A NZ79385521A NZ793855A NZ 793855 A NZ793855 A NZ 793855A NZ 793855 A NZ793855 A NZ 793855A NZ 79385521 A NZ79385521 A NZ 79385521A NZ 793855 A NZ793855 A NZ 793855A
Authority
NZ
New Zealand
Prior art keywords
pulmonary fibrosis
methods
treating pulmonary
patient
treating
Prior art date
Application number
NZ793855A
Other languages
English (en)
Inventor
Chris Burns
John Lambert
Mark Graeme Devlin
Original Assignee
Amplia Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901743A external-priority patent/AU2020901743A0/en
Application filed by Amplia Therapeutics Ltd filed Critical Amplia Therapeutics Ltd
Publication of NZ793855A publication Critical patent/NZ793855A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ793855A 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis NZ793855A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020901743A AU2020901743A0 (en) 2020-05-28 Methods of treating pulmonary fibrosis
PCT/AU2021/050457 WO2021237273A1 (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
NZ793855A true NZ793855A (en) 2026-02-27

Family

ID=78745664

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ793855A NZ793855A (en) 2020-05-28 2021-05-17 Methods of treating pulmonary fibrosis

Country Status (9)

Country Link
US (1) US20230190746A1 (https=)
EP (1) EP4157278A4 (https=)
JP (1) JP7745571B2 (https=)
KR (1) KR20230017843A (https=)
CN (1) CN115867281A (https=)
AU (1) AU2021279205B2 (https=)
CA (1) CA3177652A1 (https=)
NZ (1) NZ793855A (https=)
WO (1) WO2021237273A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3001119T3 (es) 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK
WO2023139154A1 (en) * 2022-01-19 2023-07-27 Nordic Bioscience A/S A method for detecting covid-19 in a patient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174946B2 (en) * 2011-02-17 2015-11-03 Cancer Therapeutics Crc Pty Ltd Selective FAK inhibitors
WO2014027199A1 (en) * 2012-08-14 2014-02-20 Cancer Therapeutics Crc Pty Ltd Fak and flt3 inhibitors
ES3001119T3 (es) * 2019-03-28 2025-03-04 Amplia Therapeutics Ltd Una sal y forma cristalina de un inhibidor de FAK

Also Published As

Publication number Publication date
JP7745571B2 (ja) 2025-09-29
US20230190746A1 (en) 2023-06-22
WO2021237273A1 (en) 2021-12-02
KR20230017843A (ko) 2023-02-06
CN115867281A (zh) 2023-03-28
EP4157278A4 (en) 2024-07-03
EP4157278A1 (en) 2023-04-05
AU2021279205A1 (en) 2022-12-08
JP2023527358A (ja) 2023-06-28
AU2021279205B2 (en) 2025-12-04
CA3177652A1 (en) 2021-12-02

Similar Documents

Publication Publication Date Title
MX2023002371A (es) Derivado de nitrilo que actua como inhibidor de la dipeptidil peptidasa 1 y uso del mismo.
WO2022125616A8 (en) Dialkyl tryptamines and their therapeutic uses
PH12022552261A1 (en) Crystalline hydrate of a jak inhibitor compound
NZ765795A (en) Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
NZ793855A (en) Methods of treating pulmonary fibrosis
MX2021014372A (es) Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos.
PH12023550101A1 (en) Novel compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
MY207696A (en) 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof
NZ790364A (en) Compounds and compositions for use in treating skin disorders
MX2024012335A (es) Compuestos heterociclicos antivirales
MX2024011142A (es) Tratamiento de neurofibromas cutaneos con mirdametinib.
MX2022011725A (es) Metodos para tratar una lesion pulmonar con inhibidores de cgrp.
MX2025014397A (es) Inhibidores de helicasa de adn recq del sindrome de werner (wrn)
MX2025013435A (es) Derivados de carboxamida heteroaromatica como inhibidores de la calicreina plasmatica
MX2022003845A (es) Tratamientos cognitivos medicinales.
CL2023001201A1 (es) Regímenes para tratamiento de trastornos de pérdida de cabello con inhibidores de jak deuterados
MX2022015146A (es) Tratamiento de la artritis reumatoide.
MX2022012923A (es) Inhibidores de trpc6 para tratar afecciones respiratorias.
WO2020128614A8 (en) Method for treating interstital lung disease
MX2025001642A (es) Tratamiento del cancer de piel
MX2022014523A (es) Derivado de piridina y aplicacion del mismo.
MX2021003794A (es) Derivados de tieno[3,2-b]piridina como inhibidores de la udp glicosiltransferasa y metodos de uso.
ZA202310682B (en) Nicotinamide ripk1 inhibitors
IL319025A (en) Methods for treating or preventing endometriosis
CL2023000648A1 (es) Métodos para tratar enfermedades o afecciones mediadas por pde iv

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: AMPLIA THERAPEUTICS LIMITED, AU

Effective date: 20240506